Literature DB >> 28287031

Comparison of diverse platelet activation markers as indicators for left atrial thrombus in atrial fibrillation.

Daniel Tarnowski1, David M Poitz1, Lina Plichta1, Felix M Heidrich1, Stephan Wiedemann1, Tobias Ruf1, Johannes Mierke1, Tobias Löhn1, Stefanie Jellinghaus1, Ruth H Strasser1, Karim Ibrahim1, Christian Pfluecke1.   

Abstract

Atrial fibrillation (AF) is well known for being a major risk factor of thromboembolic stroke. We could recently demonstrate an association of monocyte-platelet aggregates (MPAs) with the degree of thrombogenicity in patients with AF. This study investigated platelet activation markers, as potential biomarkers for the presence of left atrial (LA) thrombus in patients with AF. One hundred and eight patients with symptomatic AF underwent transesophageal echocardiography (TEE) before scheduled cardioversion or pulmonary vein isolation. In order to determine the content of MPAs by flow-cytometric quantification analyses, blood was drawn on the day of TEE. The soluble CD40 Ligand (sCD40L) and soluble P-selectin (sP-selectin) were obtained by Cytometric Bead Arrays (CBA). D-dimer levels were detected by quantitative immunological determination of fibrin degradation products. Clinical, laboratory, and echocardiographic standard parameters were obtained from all patients, including the determination of the flow in the left atrial appendage (LAA). Patients with detected LA thrombus (n = 28) compared with patients without thrombus (n = 80) showed an increased number of common risk factors, such as age, diabetes, heart failure, and coronary artery disease (CAD). The presence of LA thrombus was associated with significantly increased levels of MPAs (147 ± 12 vs. 304 ± 29 per µl; p < 0.00), sCD40L (106.3 ± 31.0 vs. 33.5 ± 2.1 pg/ml, p = 0.027), and D-dimer (0.13 ± 0.02 vs. 0.69 ± 0.21 mg FEU/l, p = 0.015). In contrast, sP-selectin showed no association with LA thrombus. A multivariate regression analysis showed that MPAs, sCD40L as well as D-dimers were independent indicators for the existence of LA thrombus. MPAs above 170 cells/µl indicated LA thrombus with a high sensitivity of 93% and a specificity of 73% (OR 62, 95% CI. 6.9-557.2, p < 0.001) in patients with AF, whereas the D-dimer lost their quality as independent indicator by using the conventional cut-off of 0.5 mg/l within the regression analysis. MPAs, as well as the D-dimer, correlated significantly negatively with the flow in the LAA measured during TEE. The content of MPAs, sCD40L, and D-dimer, but not sP-selectin showed an increased dependence on LA thrombus in patients with AF. In our study group, MPAs showed the best diagnostic test accuracy of the compared platelet markers. The different results of the examined platelet activation markers could be an indication of diverse mechanisms of LA thrombus in AF. Further studies should evaluate whether determination of MPAs in clinical routine may suffice to indicate the presence of LA thrombus in patients with AF.

Entities:  

Keywords:  Atrial fibrillation; D-dimer; monocyte–platelet aggregates; soluble CD40 ligand; soluble P-selectin; stroke; thromboembolism; thrombogenicity

Mesh:

Substances:

Year:  2017        PMID: 28287031     DOI: 10.1080/09537104.2017.1293805

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  8 in total

1.  Increased Levels of Platelets and Endothelial-Derived Microparticles in Patients With Non-Valvular Atrial Fibrillation During Rivaroxaban Therapy.

Authors:  Aleksandra Lenart-Migdalska; Leszek Drabik; Magdalena Kaźnica-Wiatr; Lidia Tomkiewicz-Pająk; Piotr Podolec; Maria Olszowska
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

2.  Comparison of Immature Platelet Fraction and Factors Associated with Inflammation, Thrombosis and Platelet Reactivity Between Left and Right Atria in Patients with Atrial Fibrillation.

Authors:  Olga Perelshtein Brezinov; Ziv Sevilya; Ella Yahud; Michael Rahkovich; Yonatan Kogan; Gergana Marincheva; Yana Kakzanov; Eli Lev; Avishag Laish-Farkash
Journal:  J Atr Fibrillation       Date:  2021-02-28

Review 3.  Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.

Authors:  Mario Piergiulio Pezzo; Antonella Tufano; Massimo Franchini
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

4.  Evidence-Based Case Report: The Use of D-Dimer Assay to Exclude Left Atrial Thrombus in Patient with Atrial Fibrillation >48 Hours.

Authors:  Raymond Pranata; Emir Yonas; Veresa Chintya; Alexander Edo Tondas; Sunu Budhi Raharjo
Journal:  J Atr Fibrillation       Date:  2019-04-30

Review 5.  Update on Biomarkers Associated to Cardioembolic Stroke: A Narrative Review.

Authors:  Ana Catarina Fonseca; Pedro Coelho
Journal:  Life (Basel)       Date:  2021-05-17

Review 6.  A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.

Authors:  Luxiang Shang; Ling Zhang; Yankai Guo; Huaxin Sun; Xiaoxue Zhang; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Front Cardiovasc Med       Date:  2021-07-01

Review 7.  Exosomes in atrial fibrillation: therapeutic potential and role as clinical biomarkers.

Authors:  Kun Xiang; Muhammad Akram; Walaa Fikry Elbossaty; Jinfu Yang; Chengming Fan
Journal:  Heart Fail Rev       Date:  2021-07-12       Impact factor: 4.654

8.  CD11b expression on monocytes and data of inflammatory parameters after Transcatheter Aortic Valve Implantation in dependence of early mortality.

Authors:  C Pfluecke; S Wydra; K Berndt; D Tarnowski; M Cybularz; P Barthel; A Linke; K Ibrahim; D M Poitz
Journal:  Data Brief       Date:  2020-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.